Muscarinic-3-receptor positive allosteric modulator ASP8302 in patients with underactive bladder. A randomized controlled trial.
Jan Willem Olivier van TillEri AritaKentaro KuroishiRichard CroyMatthias OelkeGommert A van KoeveringeChristopher R ChappleOsamu YamaguchiPaul AbramsPublished in: Neurourology and urodynamics (2022)
ASP8302 was safe and well tolerated in patients with UAB identified by nonurodynamic clinical criteria, but it did not show efficacy in the primary endpoint. However, in males it showed improvement of symptoms and functional parameters. BVE (using US) is a more optimal outcome measure than PVR in UAB.